{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:44Z","timestamp":1760137904147,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Council of Science and Technology of Mexico (CONACyT)","award":["SALUD-2011-1-162087"],"award-info":[{"award-number":["SALUD-2011-1-162087"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Major depressive disorder (MDD) is a major health problem in Parkinson\u2019s disease (PD) patients. We described the clinical and sociodemographic factors of MDD among patients with PD at a national neurological referral center in Mexico. One hundred patients with PD + MDD were included in the study. All the patients were evaluated during the \u201cON\u201d treatment phase of PD. Clinical scales for cognition (MMSE and MoCA) and MDD (MADRS) were applied. The mean age was 58.49 \u00b1 11.02 years, and 57% of the sample was male. The most frequent symptom of PD was tremor (67%), and onset was more frequent on the right side (57%). Additionally, 49% of the patients with PD had moderate to severe (M\/S) MDD. Selective serotonin reuptake inhibitors were the most frequent antidepressant treatment (69%). The scores of the scales were MADRS 21.33 \u00b1 5.49, MoCA 21.06 \u00b1 4.65, and MMSE 26.67 \u00b1 1.20. The females had lower MMSE scores compared to the males (p = 0.043). The patients with M\/S MDD had more rigidity at the beginning of PD (p = 0.005), fewer march alterations (p = 0.023), and a greater prevalence of left-side initial disease (p = 0.037). Rigidity was associated with M\/S MDD (OR 3.75 p = 0.013). MDD was slightly more frequent in the males than in the females. The MDD symptoms and cognitive impairment were worse in the female population.<\/jats:p>","DOI":"10.3390\/brainsci12030326","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:09:57Z","timestamp":1646078997000},"page":"326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Naturalistic Study of Depression Associated with Parkinson\u2019s Disease in a National Public Neurological Referral Center in Mexico"],"prefix":"10.3390","volume":"12","author":[{"given":"Reinhard","family":"Janssen-Aguilar","sequence":"first","affiliation":[{"name":"Department of Psychiatry, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9079-3267","authenticated-orcid":false,"given":"Patricia","family":"Rojas","sequence":"additional","affiliation":[{"name":"Laboratory of Neurotoxicology, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-0532","authenticated-orcid":false,"given":"Elizabeth","family":"Ruiz-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Laboratory of Neurotoxicology, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayela","family":"Rodriguez-Violante","sequence":"additional","affiliation":[{"name":"Movement Disorders Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yessica M.","family":"Alc\u00e1ntara-Flores","sequence":"additional","affiliation":[{"name":"Laboratory of Neurotoxicology, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7272-8119","authenticated-orcid":false,"given":"Daniel","family":"Crail-Mel\u00e9ndez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Cervantes-Arriaga","sequence":"additional","affiliation":[{"name":"Movement Disorders Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"S\u00e1nchez-Escand\u00f3n","sequence":"additional","affiliation":[{"name":"Clinic of Sleep Disorders, Metropolitan Autonomous University, Mexico City 14387, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel A.","family":"Ruiz-Chow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Institute of Neurology and Neurosurgery Manuel Velasco Su\u00e1rez, Av. Insurgentes Sur No. 3877, Mexico City 14269, Mexico"},{"name":"Liaison Psychiatry, Medical Center ABC, Av. Carlos Graef Fern\u00e1ndez 154, Mexico City 05300, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","article-title":"Epidemiology of Parkinson Disease","volume":"34","author":"Lee","year":"2016","journal-title":"Neurol. Clin."},{"key":"ref_2","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators (2021). Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 17, 939\u2013953. Erratum in Lancet Neurol. 2021, 20, e7."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3329\/bmrcb.v44i1.36799","article-title":"Risk Factors of Major Depressive Disorder in Parkinson\u2019s Disease","volume":"44","author":"Khalil","year":"2018","journal-title":"Bangladesh Med. Res. Counc. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3346\/jkms.2018.33.e300","article-title":"Psychiatric Manifestation in Patients with Parkinson\u2019s Disease","volume":"33","author":"Han","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/cjn.2021.40","article-title":"Clinical Study of 668 Indian Subjects with Juvenile, Young, and Early Onset Parkinson\u2019s Disease","volume":"49","author":"Kukkle","year":"2022","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jad.2015.05.059","article-title":"Depression rating scales in Parkinson\u2019s disease: A critical review updating recent literature","volume":"184","author":"Torbey","year":"2015","journal-title":"J. Affect. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fneur.2018.00156","article-title":"Diagnostic Criteria for Parkinson\u2019s Disease: From James Parkinson to the Concept of Prodromal Disease","volume":"9","author":"Marsili","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease (2003). The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): Status and recommendations. Mov. Disord., 18, 738\u2013750.","DOI":"10.1002\/mds.10473"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/02813432.2016.1248635","article-title":"Patients\u2019 perspectives on the use of the Montgomery-Asberg depression rating scale self-assessment version in primary care","volume":"34","author":"Wikberg","year":"2016","journal-title":"Scand. J. Prim. Health Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0025-7753(02)72429-9","article-title":"Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales","volume":"118","author":"Lobo","year":"2002","journal-title":"Med. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Larner, A.J. (2017). The Mini-Mental State Examination (MMSE): Update on Its Diagnostic Accuracy and Clinical Utility for Cognitive Disorders. Cognitive Screening Instruments, Springer. [2nd ed.].","DOI":"10.1007\/978-3-319-44775-9"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1076\/anec.11.1.1.29366","article-title":"Validation of a modified version of the Mini-Mental State Examination (MMSE) in Spanish","volume":"11","author":"Beaman","year":"2004","journal-title":"Aging Neuropsychol. Cogn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1017\/S1041610218001370","article-title":"Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer\u2019s Disease (AD) in the elderly?","volume":"31","author":"Pinto","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"ref_16","first-page":"237","article-title":"Validity and Reliability of the Spanish Version of the Montreal Cognitive Assessment (MoCA) for the Detection of Cognitive Impairment in Mexico","volume":"47","year":"2018","journal-title":"Rev. Colomb. Psiquiatr."},{"key":"ref_17","unstructured":"Juul, S. (2006). An Introduction to STATA for Health Researchers, STATA Press. [1st ed.]."},{"key":"ref_18","unstructured":"Sadock, B.J., and Sadock, V.A. (2007). Kaplan & Sadock\u2019s Synopsis of Psychiatry: Behavioral Sciences\/Clinical Psychiatry, Lippincott Williams & Wilkins Publishers. [10th ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2019.09.012","article-title":"Depression and Anxiety in Parkinson Disease","volume":"36","author":"Ray","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0891988709351833","article-title":"Occurrence risk and structure of depression in Parkinson disease with and without dementia: Results from the GEPAD Study","volume":"23","author":"Riedel","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jad.2020.09.032","article-title":"Depression in Parkinson\u2019s disease: Perspectives from an Australian cohort","volume":"277","author":"Lubomski","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2147\/NDT.S300596","article-title":"Depression and Related Factors in Patients with Parkinson\u2019s Disease at High Altitude","volume":"17","author":"Cao","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.34172\/icnj.2021.18","article-title":"Prevalence of Depression and Anxiety and Related Factors in Patients with Parkinson\u2019s Disease: Depression and Anxiety in Parkinson\u2019s Disease","volume":"8","author":"Eydivandi","year":"2021","journal-title":"Int. Clin. Neurosci. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3389\/fpsyt.2018.00723","article-title":"An Investigation on the Clinical Features and Neurochemical Changes in Parkinson\u2019s Disease with Depression","volume":"9","author":"Lian","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/CON.0000000000000764","article-title":"Parkinson disease","volume":"25","year":"2019","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fnins.2019.00255","article-title":"Tremor-dominant in Parkinson disease: The relevance to iron metabolism and inflammation","volume":"13","author":"Lian","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_27","first-page":"e0162254","article-title":"The characteristics of non-motor symptoms in drug-naive Parkinson\u2019s disease: Analysis between tremor dominant and non-tremor dominant subtypes","volume":"11","author":"Youn","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-0404.1994.tb01655.x","article-title":"Risk-factors for Parkinson\u2019s disease: Case-control study in the province of Caceres, Spain","volume":"89","author":"Morano","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.wnl.0000271883.45010.8a","article-title":"Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease","volume":"69","author":"Simon","year":"2007","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clineuro.2005.08.002","article-title":"The effect of depression on motor function and disease severity of Parkinson\u2019s disease","volume":"108","author":"Papapetropoulos","year":"2006","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.parkreldis.2008.09.003","article-title":"The association between motor subtypes and psychopathology in Parkinson\u2019s disease","volume":"15","author":"Reijnders","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clineuro.2017.10.031","article-title":"Depression and associated factors in nondemented Chinese patients with Parkinson\u2019s disease","volume":"163","author":"Zhu","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_33","first-page":"6434689","article-title":"Association of Gait Characteristics and Depression in Patients with Parkinson\u2019s Disease Assessed in Goal-Directed Locomotion Task","volume":"2017","author":"Kincses","year":"2017","journal-title":"Parkinsons Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3906\/sag-1603-101","article-title":"Depression and Parkinson disease: Prevalence, temporal relationship, and determinants","volume":"47","author":"Bora","year":"2017","journal-title":"Turk. J. Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1590\/1980-57642018dn13-010008","article-title":"Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination","volume":"13","author":"Valverde","year":"2019","journal-title":"Dement. Neuropsychol."},{"key":"ref_36","first-page":"363","article-title":"Versiones en espa\u00f1ol del Minimental State Examination (MMSE). Cuestiones para su uso en la practica clinica [Spanish versions of the Minimental State Examination (MMSE). Questions for their use in clinical practice]","volume":"61","author":"Contador","year":"2015","journal-title":"Rev. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fneur.2020.00180","article-title":"Progressive Supranuclear Palsy\u2014Parkinsonism Predominant (PSP-P)\u2014A Clinical Challenge at the Boundaries of PSP and Parkinson\u2019s Disease (PD)","volume":"11","author":"Alster","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1007\/s10072-021-05601-8","article-title":"\u201cParkinson\u2019s disease\u201d on the way to progressive supranuclear palsy: A review on PSP-parkinsonism","volume":"42","author":"Miroslav","year":"2021","journal-title":"Neurol. Sci."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/3\/326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:15Z","timestamp":1760135355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/3\/326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["brainsci12030326"],"URL":"https:\/\/doi.org\/10.3390\/brainsci12030326","relation":{},"ISSN":["2076-3425"],"issn-type":[{"type":"electronic","value":"2076-3425"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}